Compare Abeona Therapeutics Inc (ABEO) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Live Nation Entertainment, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.62 (market cap $424.33M), while Live Nation Entertainment, Inc. trades at $183.14 (market cap $43.01B). The key difference: Live Nation Entertainment, Inc. is far larger — about 101.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Live Nation Entertainment, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | LYV | |
|---|---|---|
Market Cap | $424.33M | $43.01B |
Sector | Health | Industrials |
52-Week High | $7.45 | $186.59 |
52-Week Low | $4.17 | $125.61 |
Enterprise Value | $279.23M | $45.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Live Nation (LYV) trades at $180.66, down 0.61% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $209.54. The company reported Q2 2026 EPS of $1.05, beating estimates, and revenue growth driven by strong concert demand. However, valuation metrics like a P/E of 117.49 and a P/B of 511.19 appear elevated, while net income margin remains thin at 0.51% for 2025.
The outlook is supported by robust fan attendance and raised full-year expectations, but risks include high debt levels, legal uncertainties, and cost pressures. With 87% of analysts rating it a buy, the stock offers growth potential contingent on execution amid competitive and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
